Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND) and Emergent Biosolutions (EBS)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascendis Pharma (ASND) and Emergent Biosolutions (EBS) with bullish sentiments.

Ascendis Pharma (ASND)

Wells Fargo analyst Jim Birchenough maintained a Buy rating on Ascendis Pharma on December 6. The company’s shares closed last Monday at $107.56.

According to TipRanks.com, Birchenough is a 5-star analyst with an average return of 21.3% and a 50.4% success rate. Birchenough covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Crispr Therapeutics AG, and Ionis Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ascendis Pharma with a $160.67 average price target, implying a 46.4% upside from current levels. In a report issued on December 3, Leerink Partners also reiterated a Buy rating on the stock with a $152.00 price target.

See today’s analyst top recommended stocks >>

Emergent Biosolutions (EBS)

Wells Fargo analyst David Maris maintained a Buy rating on Emergent Biosolutions on December 6. The company’s shares closed last Monday at $54.98.

According to TipRanks.com, Maris ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -6.3% and a 37.2% success rate. Maris covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries, Amphastar Pharmaceuticals, and Bausch Health Companies.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Emergent Biosolutions with a $69.00 average price target, implying a 30.1% upside from current levels. In a report issued on November 25, Guggenheim also maintained a Buy rating on the stock with a $63.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts